» Articles » PMID: 17526829

Biofilm Exclusion of Uropathogenic Bacteria by Selected Asymptomatic Bacteriuria Escherichia Coli Strains

Overview
Specialty Microbiology
Date 2007 May 29
PMID 17526829
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Many bacterial infections are associated with biofilm formation. In the urinary tract bacterial biofilms develop on both living surfaces and artificial implants, producing chronic and often intractable infections. Escherichia coli is the most common organism associated with urinary tract infections. In contrast to uropathogenic E. coli (UPEC), which cause symptomatic urinary tract infection, asymptomatic bacteriuria (ABU) strains are associated with essentially symptom-free infections. Here the biofilm-forming capacity on abiotic surfaces of selected E. coli ABU strains and UPEC strains in human urine was investigated. It was found that there is a strong bias for biofilm formation by the ABU strains. Not only were the ABU strains significantly better biofilm formers than UPEC strains, they were also able to out-compete UPEC strains as well as uropathogenic strains of Klebsiella spp. during biofilm formation. The results support the notion of bacterial prophylaxis employing selected ABU strains to eliminate UPEC strains and other pathogens in patients prone to recalcitrant infections.

Citing Articles

Biofilm forming properties of quinolone resistant Escherichia coli from the broiler production chain and their dynamics in mixed biofilms.

Nesse L, Osland A, Mo S, Sekse C, Slettemeas J, Bruvoll A BMC Microbiol. 2020; 20(1):46.

PMID: 32131730 PMC: 7055085. DOI: 10.1186/s12866-020-01730-w.


Characteristics of Dogs with Biofilm-Forming Escherichia Coli Urinary Tract Infections.

Kern Z, Jacob M, Gilbertie J, Vaden S, Lyle S J Vet Intern Med. 2018; 32(5):1645-1651.

PMID: 30084122 PMC: 6189388. DOI: 10.1111/jvim.15231.


Probiotic Escherichia coli inhibits biofilm formation of pathogenic E. coli via extracellular activity of DegP.

Fang K, Jin X, Hong S Sci Rep. 2018; 8(1):4939.

PMID: 29563542 PMC: 5862908. DOI: 10.1038/s41598-018-23180-1.


Innate Immune Responses to Bladder Infection.

Hayes B, Abraham S Microbiol Spectr. 2017; 4(6).

PMID: 28084200 PMC: 5242417. DOI: 10.1128/microbiolspec.UTI-0024-2016.


Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.

OBrien V, Hannan T, Nielsen H, Hultgren S Microbiol Spectr. 2016; 4(1).

PMID: 26999391 PMC: 4887100. DOI: 10.1128/microbiolspec.UTI-0013-2012.